Myeloma is currently known as a terminal blood cancer. There is no cure, however there are many new treatments on the horizon which show great promise. Clinical trials are the gateway to accessing these new treatments, but not all myeloma patients are created equal when it comes to clinical trial eligibility. Geoff Nyssen wants to … Continued
Clinical trials are often the gateway to new treatments for patients with blood cancer. When new therapies are being tested they go through various stages. If you have ever wondered about the various clinical trial stages and what they mean, below is a synopsis to provide you with some insight. Phase I trials are the … Continued
In the last six weeks the U.S. Food and Drug Administration (FDA) has approved five additional treatments for blood cancer. The rate at which new treatments are being approved in the U.S. is incredibly encouraging. It demonstrates the progress researchers are making in finding new and novel ways to treat cancer. It is also frustrating … Continued
In June 2019, the U.S. FDA approved selinexor (Xpovio) in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. Myeloma patients had to have been treated with at least four prior therapies. In November 2020, the results of the BOSTON study were published which demonstrated the benefits of using selinexor earlier in … Continued
Two new research projects co-funded through a partnership between America’s The Leukemia & Lymphoma Society (LLS), Snowdome Foundation and Leukaemia Foundation will focus on acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS), seeking to improve understanding and treatment of these blood cancers. Prof. Ravindra Majeti, Stanford University in the US, will join with Assoc. Prof. … Continued
Professor Pimanda is incredibly curious. His observations around why cells behave in certain ways and respond variably to stimuli led him down a cell biology research path. He was particularly drawn to blood stem cell development and maturation and the disruption of this orderly process in blood cancers. In 2008, when John was setting up … Continued
Genetics is complex! At a very basic level we understand that when genes are altered or mutated the end result is a disease. This can take the form of hereditary diseases such as cystic fibrosis, sickle cell anaemia or Huntington’s disease for example. However, gene mutations can also be spontaneous and sometimes result in cancer. … Continued
Professor Mark Dawson has been awarded the 2020 Frank Fenner Prize for Life Scientist of the Year. This prestigious award is one of the Australian Prime Minister’s Prizes for Science which recognises the contributions our scientists, innovators and science teachers make to Australia’s scientific commercialisation capabilities. Professor Dawson is both a haematologist clinician as well … Continued
For the first time, the Snowdome Foundation pivoted its annual Blood Sweat and Tears of Joy educational event from face-to-face to virtual. This increased access and participation, enabling involvement from speakers in the USA, Western Australia, Victoria, South Australia and New South Wales! The event showcased the extraordinary depth of blood cancer research and clinician … Continued